Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;91(5):697-703.
doi: 10.1007/s00277-011-1357-2. Epub 2011 Nov 11.

Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement

Moo-Kon Song  1 , Joo-Seop Chung  2 , Ho-Jin Shin  1 , Sang-Min Lee  3 , Su-Ee Lee  4 , Ho-Sup Lee  5 , Gyeong-Won Lee  6 , Seong-Jang Kim  7 , Seok-Mo Lee  8 , Dong-Seop Chung  9
Affiliations

Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement

Moo-Kon Song et al. Ann Hematol. 2012 May.

Abstract

The objective of this study was to investigate whether metabolic tumor volume (MTV) by positron emission tomography (PET) can be a potential prognostic tool when compared with Ann Arbor stage, in stages II and III nodal diffuse large B cell lymphoma (DLBCL). We evaluated 169 patients with nodal stages II and III DLBCL who underwent measurements with PET prior to rituximab combined with cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP). Cutoff point of MTV was measured using the receiver operating characteristic (ROC) curve. During a median period of 36 months, stage II was 59.2% and III was 40.8%. Using the ROC curve, the MTV of 220 cm(3) was the cutoff value. The low MTV group (<220 cm(3)) had longer progression-free survival (PFS) and overall survival (OS), compared with the high MTV group (≥220 cm(3)) (p < 0.001, p < 0.001). Stage II patients had longer survival than those in stage III (PFS, p = 0.011; OS, p = 0.001). The high MTV group had lower PFS and OS patterns, regardless of stage, compared with the low MTV group (p < 0.001, p < 0.001). Multivariate analysis revealed an association of the high MTV group with lower PFS and OS (PFS, hazard ratio (HR) = 5.300, p < 0.001; OS, HR = 7.009, p < 0.001), but not stage III (PFS, p = 0.187; OS, p = 0.054). Assessment of MTV by PET had more potential predictive power than Ann Arbor stage in the patients that received R-CHOP.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Receiver operating characteristic curve analysis in survival prediction according to MTV in 160 stages II and III nodal DLBCL patients (continuous variable). Area under the curve was 0.857 (p < 0.001, 95% CI 0.782–0.932), and 220 cm3 was determined as the cutoff value of MTV for comparison. Sensitivity and specificity of the dichotomized MTV (≥220 versus <220) were 91.7% and 65.3%, respectively
Fig. 2
Fig. 2
Comparisons of survival according to the cutoff value of MTV and stage combined with the cutoff value of MTV. a PFS and b OS according to the cutoff value of MTV were higher in the low MTV group compared with the high MTV group (PFS <0.001; OS, p < 0.001, respectively). c PFS and d OS of stages II and III with the low MTV groups were higher compared with other groups, whereas survival between the two low MTV groups (PFS 90.5% in stage II versus 88.0% in stage III, p = 0.703; OS 95.2% in stage II versus 88.0% in stage III, p = 0.268) or high MTV groups (PFS 60.5% in stage II versus 51.2% in stage III, p = 0.347; OS 65.8% in stage II versus 51.2% in stage III, p = 0.175) were not different
See this image and copyright information in PMC

References

    1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242. doi: 10.1056/NEJMoa011795. - DOI - PubMed
    1. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484–1493. doi: 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I. - DOI - PubMed
    1. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–1006. doi: 10.1056/NEJM199304083281404. - DOI - PubMed
    1. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–633. doi: 10.1182/blood-2003-06-2094. - DOI - PubMed
    1. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–4126. doi: 10.1200/JCO.2005.09.131. - DOI - PubMed

Publication types

MeSH terms

Substances